NCT01992952 2025-11-26
FAKTION
Velindre NHS Trust
Phase 1/2 Active not recruiting
Clinical Trials
12 trialsNCT05359783 2025-03-28
MAGSNOW
Vastra Gotaland Region
Phase 1/2 Completed
NCT06788197 2025-03-26
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
Henan Cancer Hospital
Phase 1/2 Not yet recruiting
NCT06880029 2025-03-19
CIRCADIAN
Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Phase 1/2 Recruiting
NCT05176080 2024-12-17
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
Henan Cancer Hospital
Phase 1/2 Terminated
NCT05019690 2024-09-19
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
Fujian Cancer Hospital
Phase 1/2 Recruiting
NCT05335473 2023-04-06
Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
Henan Cancer Hospital
Phase 1/2 Unknown
NCT04213898 2019-12-30
SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer
Henan Cancer Hospital
Phase 1/2 Unknown
NCT03518268 2019-01-17
Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor
Tel-Aviv Sourasky Medical Center
Phase 1/2 Unknown
NCT01939418 2017-10-03
Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
National Cancer Center, Korea
Phase 1/2 Terminated
NCT00825682 2016-12-08
The Effect of Reflexology on Radiation-related Fatigue in Breast Cancer Patients
Sheba Medical Center
Phase 1/2 Completed
NCT02781155 2016-05-24
Limiting Chemotherapy Side Effects by Using Moxa
East and North Hertfordshire NHS Trust
Phase 1/2 Unknown